SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 16, 2022, between IMV Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
LEASE BETWEEN TNC 120-140 EILEEN STUBBS LTD. AND IMMUNOVACCINE TECHNOLOGIES INC.Lease Agreement • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations • Nova Scotia
The following are certain basic terms and provisions of this Lease (the “Basic Provisions”), which Basic Provisions form part of this Lease and are in certain instances referred to in subsequent sections of this Lease. Any conflict or inconsistency between the Basic Provisions and the other provisions of this Lease shall be resolved in favour of such other provisions.
CERTAIN INFORMATION (INDICATED BY [***]) HAS BEEN EXCLUDED FROM THE VERSION OF THIS DOCUMENT FILED AS AN EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Employment Contract • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations
BETWEEN: IMV USA INC., a corporation incorporated pursuant to the laws of the State of Delaware and having its registered office at 10 Rogers Street, Suite 120 and 121, Cambridge, Massachusetts, 02142-1288;
THIS EMPLOYMENT CONTRACT made effective as of September 15, 2022 BETWEEN:Employment Agreement • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations
WHEREAS the Corporation carries on the business of developing T cell-activating cancer immunotherapies based on the Company’s proprietary drug delivery platform.;
THIS EMPLOYMENT CONTRACT made effective as of the June 14, 2021 BETWEENEmployment Agreement • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations
WHEREAS the Corporation carries on the business of developing T cell-activating cancer immunotherapies based on the Company’s proprietary drug delivery platform.;
DEFERRED Share Unit grant letterDeferred Share Unit Grant Letter • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations
This deferred share unit grant letter is entered into between IMV Inc. (the “Corporation”) and the Participant named below pursuant to the Corporation’s deferred share unit plan (the “Plan”), a copy of which is incorporated by reference herein, and confirms the following Deferred Share Unit grant on the terms set out below and as further set out in the Plan:
LICENSE AGREEMENT BETWEEN MERCK KGaA AND IMMUNOVACCINE TECHNOLOGIES, INC. DATED LICENSE AGREEMENTLicense Agreement • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations • London
This License Agreement (hereinafter referred to as “Agreement”) is made and effective as of the 12 day of July, 2010 (the “Effective Date”), by and between MERCK KGaA, a German company with a principal place of business located at Frankfurter Stralle 250, 64293 Darmstadt, German , [***] (hereinafter collectively referred to as “Merck”), and IMMUNOVACCINE TECHNOLOGIES, INC. (hereinafter referred to as “Immunovaccine”), a Canadian corporation with a principal place of business located at 1819 Granvill Street, Suite 303, Halifax, Nova Scotia B3J 3R1, Canada. Merck and Immunovaccine are each referred to herein as a “Party” and collectively as the “Parties,” except as may otherwise be provided in this Agreement.
LEASELease • March 16th, 2023 • IMV Inc. • Pharmaceutical preparations • Massachusetts
This lease (the “Lease”) is dated as of July 26th, 2021, between GiGi Capital, LLC having a place of business at 10 Rogers Street #121, Cambridge, MA 02142 (the “Lessor”) and IMV USA INC. a Delaware Corporation., presently having its normal place of business at 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia, B3B 2C4, Canada (the “Lessee”). The Lessor and the Lessee hereby agree as follows:
